Clinical Trials in China / NCT06268262
Recruiting
Observational
Surgical-imaging Research on Obesity (SIRO)
NCT06268262 · tracked via the Priya Life Science China tracker
Condition(s) studied
Overweight and Obesity
Study summary
The global obesity epidemic is well established, and is an important public health issue. The previous researches had applied the clues that obesity is a kind of systemic disease. The investigators hypothesized that a serious alteration of the body systems will occur after bariatric surgery, which may shed light on the mechanisms of obesity. Thus, the research aims to combine the imaging and surgery to investigate the alterations of the body that induced by obese and alterations after surgery.
Eligibility
Inclusion Criteria for obesity group:
Meeting the obesity criteria (BMI \> 28); 2) Meeting the indications for bariatric surgery, planning to undergo surgery for the first time; 3) Age between 18-65 years old, no gender restrictions; 4) Right-handed, of Han ethnicity; 5) Informed consent to the study, willing to cooperate with the research, and able to sign an informed consent form.
Inclusion Criteria for the Control Group:
1. Healthy volunteers with a BMI between 18.5-23.9;
2. Age between 18-65 years old, no gender restrictions;
3. Right-handed, of Han ethnicity;
4. Informed consent to the study, willing to cooperate with the research, and able to sign an informed consent form.
Exclusion Criteria for obesity group:
1. Secondary obesity caused by other organic diseases or medication (such as hormone use, etc.);
2. Unable to undergo surgery as planned;
3. Pregnant or breastfeeding;
4. Low cognitive ability and incapable of cooperating with the study;
5. Eating disorders;
6. Alcohol or drug dependence;
7. Meeting the criteria for organic mental disorders, severe mental disorders (schizophrenia, etc.), or other serious mental illnesses requiring clinical intervention;
8. Contraindications for MR scanning (pacemakers, cochlear implants, metal objects in the body, claustrophobia, weight exceeding the machine's load limit, etc.);
9. History of neurological organic diseases (brain tumors, epilepsy, cerebrovascular accidents, severe head trauma, etc.);
10. History of congenital heart disease (myocardial infarction, severe arrhythmias, heart failure, cardiomyopathy, rheumatic heart disease, congenital heart disease, etc.);
11. Severe liver, kidney, lung, digestive dysfunction, endocrine, and blood system diseases;
12. Active infections within the last two weeks (fever, upper respiratory infection, acute gastroenteritis, etc.);
13. Use of drugs affecting the nervous system or psychotropic drugs within the last six months.
Exclusion Criteria for the Control Group:
The same criteria as points 3) to 13) above.
Primary outcome measure(s)
- Imaging parameters of obesity — baseline, 6th month
Brain cortical thickness in millimeter - Imaging parameters of obesity — baseline, 6th month
The volume of left ventricle in cubic millimeter - Imaging parameters of obesity — baseline, 6th month
Fat fraction of liver (dividing the in-phase fat attenuation signal by the out-phase fat attenuation signal)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Affiliated Hospital of Xuzhou Medical University | Xuzhou | Jiangsu | Recruiting |
More The Affiliated Hospital of Xuzhou Medical University trials in China
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06268262 on ClinicalTrials.gov ↗ ← All trials in China